AI model predicts future lung cancer risk from a single low-dose chest CT scan
“A deep learning model was able to predict future lung cancer risk from a single low-dose chest CT scan, according to new research published at the ATS 2025 International Conference. The model, called Sybil, which was originally developed using National Lung Screening Trial (NLST) data by investigators from the Massachusetts Institute of Technology and Harvard Medical School, could be used to guide more personalized lung cancer screening strategies.”
Younger Patients With Lung Cancer Often Have Targetable Biomarkers
“Key Takeaways: Younger lung cancer patients frequently have targetable biomarkers, allowing for personalized therapies that can improve survival rates. Targeted therapies differ from traditional treatments, focusing on specific genetic changes, but may lead to resistance and require ongoing testing.”
More women under 65 are being diagnosed with lung cancer, Maryland doctor says
“A recent American Cancer Society study found that lung cancer incidence is now higher in women than in men under age 65. Women who have never smoked are more than twice as likely as men who have never smoked to develop the disease.”
Mutation profiles and clinicopathological correlations in lung squamous cell carcinoma
“Our study identified novel mutations and their relationships, such as NF1, PTEN, and PIK3CA, which have not been previously reported in LSCC and may have significant therapeutic and prognostic implications. Given the molecular heterogeneity observed in LSCC, it is imperative to ascertain the mutational profile in all LSCC patients to identify driver mutations that are amenable to targeted therapy. Our data suggest that certain histopathological features may be associated with mutations, providing reliable information to enhance treatment and follow-up decisions.”
Camrelizumab/Apatinib Plus Chemotherapy May Show Promise in ES-SCLC
“Combining camrelizumab and apatinib with chemotherapy as frontline treatment demonstrated promising activity in a small cohort of patients with extensive-stage small cell lung cancer (ES-SCLC), according to findings from a phase 1 study (NCT05001412) published in Signal Transduction and Targeted Therapy.”
More evidence links physical activity with improved cancer survival
“A new large analysis led by American Cancer Society (ACS) researchers shows engaging in leisure-time moderate-to-vigorous physical activity (MVPA) after a cancer diagnosis improves survival for people with several cancer types, including bladder, breast, colon, endometrial, kidney, lung, oral, prostate, rectal, and respiratory cancer.”
I Have Stage IV Lung Cancer and Still Consider Myself the Luckiest Man in the World
“My goal is to live long enough to benefit from the next treatment breakthrough—and the next.”
Congress Votes to Allow Polluters to Increase Cancer-Causing Pollution
“Today, the U.S. House of Representatives passed a Congressional Review Act Resolution of Disapproval (CRA) to repeal an important air pollution rule. The resolution was already passed by the Senate and, if it is signed into law, it will be the first drastic weakening of the Clean Air Act. The CRA would repeal a rule that helped ensure polluting facilities monitored and controlled their emissions and will likely lead to those facilities increasing the levels of toxic air pollution they emit.”
Novel Partnership Aims to Advance ctDNA Testing in Non-Small Cell Lung Cancer
“Cleveland Clinic, the University of Minnesota and University of Cambridge receive $1M grant to develop point-of-care biosensor for early detection and treatment personalization.”
FDA Grants Fast Track Designation to ZL-1310 in Small Cell Lung Cancer
“Key Takeaways: ZL-1310, targeting DLL3, shows early antitumor activity in extensive-stage SCLC, with 74% of patients experiencing tumor shrinkage or disappearance. The FDA’s fast track designation for ZL-1310 underscores the urgent need for new SCLC treatments and supports accelerated development.”
